Background / Context
For centuries, humans regarded light within the body as metaphorical only—‘the light of inspiration’, ‘the gleam of intellect’, or ‘the spark of the soul’. In modern science, biological light does exist—but is typically associated with organisms like jellyfish, marine worms, or fungi: all using the enzyme *luciferase* to convert *luciferin* into light. Yet, since the 1970s, a controversial hypothesis began emerging: do human cells also intrinsically emit photons—the elementary particles of light? This theory was spurred by observations that free radicals (such as reactive oxygen species), generated during cellular respiration, can trigger low-energy photon emission via molecular excitation—particularly within mitochondria, the cell’s ‘power plants’. Unlike animal bioluminescence, which relies on specialized proteins, human biophotons originate from *mitochondrial oxidative reactions*, a universal process in every nucleated cell.
In 2003, a research team at Kyoto University, led by Professor Masaki Kobayashi, began systematic experiments using *photomultiplier tubes* (PMTs)—devices capable of detecting as few as a single photon—in electromagnetically shielded, absolutely dark rooms. They discovered that rat brain tissue—and subsequently post-mortem human brain tissue—emitted continuous light across a spectrum of 350–650 nm, spanning ultraviolet to visible red. More surprisingly, the emission pattern was not random. It exhibited daily fluctuations (circadian rhythms), increased during sensory stimulation, and dropped sharply under anesthesia—strong evidence that it is tightly coupled to neurophysiological activity, not merely background metabolism.
Development / Key Facts
The first open-access study directly confirming human brain biophotons was published in the *Journal of Photochemistry and Photobiology B: Biology* in 2009. The Japanese team measured volunteer patients while awake, during REM sleep, and in deep NREM sleep—using a custom-designed PMT helmet. Results showed photon emission rates increased by 28% during REM sleep compared to wakefulness, and decreased by 42% during NREM stage 3 sleep, the phase of maximal neural recovery. Even more intriguingly, the spatial emission pattern was non-uniform: prefrontal and temporal cortical regions showed the highest photon density—areas involved in decision-making, working memory, and language processing.
A real-world example comes from the neuropsychiatry clinic in Hamburg, Germany, where physicians used a portable biophoton detection system to monitor epilepsy patients. In one case, a patient experienced a visual aura 90 seconds before clinical seizure onset—and the biophoton record revealed a 170% surge in photon emission in the occipital lobe precisely at that moment, far before EEG detected significant electrical changes. This suggests biophotons may serve as an *early indicator of hyper-synchronous neuronal activity*—an additional layer of information inaccessible to conventional techniques. A striking comparison can be drawn with PET scans: whereas PET measures glucose metabolism using radioactive isotopes and requires ionizing radiation, biophoton imaging is fully non-invasive, radiation-free, and potentially offers sub-millisecond temporal resolution—because photons travel at light speed, not molecular diffusion rates.
Impact / Implications
The practical impact of this phenomenon is expanding rapidly. At Stanford University, a biophysics team is developing a ‘neurophotonics chip’—a silicon microchip implantable beneath the scalp to monitor photon emission in real time and transmit data wirelessly via low-power Bluetooth. Prototypes tested on rhesus monkeys demonstrated the ability to identify the onset of clinical depression two days before behavioral symptoms appeared—based on shifts in the blue-to-green spectral component of emission. Globally, the European research agency (EU Horizon 2020) has approved €12.4 million in funding for the *LUMEN-Brain* project, aiming to build a biophoton-based early-screening device for Alzheimer’s disease with 94.7% sensitivity and 91.3% specificity, far surpassing costly and invasive cerebrospinal fluid biomarkers.
Yet the deepest implications may be philosophical and theoretical. Several theoretical physicists—including Professor Fritz-Albert Popp, a pioneer of biophoton research in the 1970s—argue that this light may play a role in *intracellular quantum coherence*, i.e., synchronization of quantum states among molecules within neurons. If true, this opens the possibility that consciousness is not merely the product of neuronal computation, but also involves coherent quantum phenomena—a notion previously deemed speculative, yet now supported by empirical evidence from single-photon spectroscopy. In other words, the light generated by our brains may not be mere ‘waste’, but an *as-yet-undeciphered intracellular communication channel*—a biological ‘optical internet’ operating at the molecular level.
Perspectives & Future Directions
Although still in the early stages of clinical translation, neural biophotonics stands on the brink of a diagnostic revolution. Within five years, portable devices priced below RM3,000 may become available to neurology clinics across ASEAN countries, enabling early dementia screening without expensive MRI or invasive lumbar punctures. Further ahead, integrating biophotonics with *brain-computer interface* (BCI) technology could yield a new generation of interfaces that interpret cognitive intent—not via coarse electrical signals, but through the spectral and temporal patterns of neuronal light—paving the way for direct brain-machine communication with unprecedented precision. As Dr. Lena Tanaka of the Tokyo Institute of Neurophotonics stated: *‘We are no longer just listening to the brain—we are now beginning to see it speak in its own light.’*